About Me
I’m a triple board-certified physician in Medical Oncology, Hematology, and Internal Medicine. I chose this field because of the deep, meaningful relationships I get to build with patients and their families. For me, cancer care is not just about treating disease—it’s about listening, supporting, and walking alongside people during some of life’s most difficult moments.
I believe in personalized, compassionate care that’s grounded in the latest medical research but always tailored to each patient’s unique values, goals, and story. Whether we’re discussing treatment options or navigating uncertainty together, my goal is to make sure you feel heard, supported, and empowered every step of the way.
I joined MetroHealth in 2024 and also serve as a Clinical Assistant Professor at Case Western Reserve University School of Medicine. It’s an honor to care for this community and to help guide patients through their journey with empathy and clarity.
Beyond his clinical practice, Dr. Attallah is deeply engaged in cutting-edge cancer research, quality improvement initiatives, and medical education. His research interests include exploring technology-assisted symptom monitoring, the application of artificial intelligence in clinical trial matching, and addressing the social determinants of health that impact patient outcomes. He also serves as a Principal Investigator on national oncology trials and actively participates in multidisciplinary tumor boards to ensure comprehensive patient care informed by the latest advancements.
Dr. Attallah's commitment to excellence has been recognized with multiple honors, including the Champion of Care recognition for outstanding clinical service and the Excellence in Teaching award for his dedication to mentoring and academic leadership. These accolades underscore his ongoing commitment to providing compassionate care, driving continuous improvement, and shaping the next generation of oncology professionals.
PubMed Publications
- Oxaliplatin Antibody-Related Thrombocytopenia: A Case Report Abstract: Oxaliplatin is used in combination with fluorouracil and leucovorin as part of the FOLFOX (fluorouracil, leucovorin, and oxaliplatin) regimen for colorectal cancer (CRC). Oxaliplatin has been shown to cause thrombocytopenia in a majority of CRC patients receiving this drug. Although this thrombocytopenia mainly occurs through myelosuppression, in rare cases, it can be immune-mediated. However, unlike other chemotherapy-induced myelosuppression, oxaliplatin-induced thrombocytopenia presents with...
- Obese communities among the best predictors of COVID-19-related deaths Abstract: CONCLUSION: This article shows a tight correlation between average BMI, food supply per country, and COVID-19-related deaths. Such predisposing factors might operate by upregulating the inflammation pathway in heavily struck countries, leading to easier triggering of the infamous cytokine storm syndrome. Obesity also increases cardiovascular and respiratory morbidities, which are coupled to increased ICU demand and deaths among infected cases.Video abstract: http://links.lww.com/CAEN/A25.
- Intracranial rosai-dorfman: a clinical challenge Abstract: Rosai-Dorfman disease has been described as massive painless cervical lymphadenopathy with a benign clinical course and unclear etiology. Isolated extranodal involvement has been rarely described. We present a rare case of isolated intracranial Rosai-Dorfman disease that was diagnosed and treated at our institution. Our diagnostic and clinical challenges are presented with a review of the literature.
Education & Training
Education
Residency
Ascension St. John Hospital – Internal MedicineMedical Education
Assiut University Faculty of Medicine MDInternship
Ascension St. John Hospital – Internal MedicineFellowship
Ascension St. John Hospital – Hematology/Medical OncologyBoard Certifications
American Board of Internal Medicine - Internal MedicineAmerican Board of Internal Medicine - Medical Oncology
American Board of Internal Medicine - Hematology